Lazap (Olanzapine)

Olanzapine works by blocking dopamine D2 receptors and serotonin 5‑HT2A receptors in the brain, which reduces excessive dopaminergic and serotonergic activity linked to psychosis and mood swings. Its additional activity at histamine, muscarinic and adrenergic receptors contributes to its overall therapeutic profile.

The appropriate dose of Lazap is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy and tolerability. Dosage may be adjusted over time, and patients should follow the prescribing information provided by their healthcare professional.

Data on olanzapine use in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss risks and alternatives with their physician.

To order Lazap, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other atypical antipsychotics such as risperidone or quetiapine, olanzapine often shows strong efficacy in controlling psychotic symptoms but is associated with a higher propensity for metabolic side effects like weight gain and glucose elevation. Choice of therapy depends on individual patient factors and risk‑benefit assessment.

Lazap tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

Lazap is taken orally as a tablet. The tablet should be swallowed whole with water, preferably at the same time each day. Patients should not crush, split or chew the tablet unless specifically instructed by a healthcare professional.

Serious risks include neuroleptic malignant syndrome, agranulocytosis, severe hyperglycemia, seizures, tardive dyskinesia and myocarditis. Patients should be educated to seek immediate medical attention if they experience high fever, muscle rigidity, unexplained infections, rapid weight gain, or involuntary movements.

Lazap is contraindicated in individuals with known hypersensitivity to olanzapine or any of its excipients. Caution is advised for patients with uncontrolled diabetes, severe cardiovascular disease, hepatic impairment, or a history of neuroleptic malignant syndrome. Pregnant or breastfeeding women should only use it after thorough risk assessment.